CancerNetwork Members: Login | Register
Become a fan on  Facebook  Add us on  Google Plus Follow us on  Twitter Join us on LinkedIn Sign up for our Newsletters Subscribe to our RSS Feed

 

CancerNetwork SearchMedica Medline Drugs

Powered by SearchMedica

 
PUBLICATIONS
NEWS
PODCASTS
TOPICS
BLOGS
NURSES
PATIENTS
JOBS
CONFERENCES
CME
SUPPLEMENTS
 

Home »

ONCOLOGY. Vol. 15 No. 11
Pages: 1  2  
Next
 

Ohio Dental Association Not Giving Lip Service to New Smokeless Tobacco Product

November 1, 2001

The Ohio Dental Association (ODA) strongly advocates against the use of smokeless tobacco products because of their harmful effects—particularly the strong link to oral cancer. As a result, the ODA discounts the advertising hype that appears to be surrounding a new smokeless tobacco product called Revel, a "socially acceptable" alternative to cigarettes. Youngstown, Ohio, is one of two cities where Revel will initially be marketed for 6 months.

Smokeless tobacco, in any form, is dangerous to health, said Cleveland dentist Dr. Bruce Grbach, chairman of the ODA’s council on communication and public service, which oversees Operation TACTIC (Teens Against Chewing Tobacco in the Community)—a program aimed at discouraging use and raising awareness of the harmful effects of smokeless tobacco products among elementary through high school students.

Nicotine in Any Form Is Harmful

Dr. Grbach questions the use of Revel as an alternative to smoking, stating that nicotine(Drug information on nicotine) in any form is harmful. "There are a number of studies that demonstrate that smokeless tobacco is dangerous and can cause oral cancer. This new product is a form of smokeless tobacco, and consumers should know that using this product exposes them to risks of oral cancer."

Revel is being introduced only in Youngstown, Ohio, and Topeka, Kansas, by the US Smokeless Tobacco Co. It is described as a form of smokeless tobacco that does not induce the need to expectorate, with no unpleasant tobacco flavor, and that is "a blend of premium tobaccos and fresh mint flavor in clean and neat, discrete, easy-to-use packs." Users will need to spit the wet packet out when finished.

Dr. Nancy Goorey, DDS, of Columbus, who has been active for years in programs that discourage the use of smokeless tobacco and is current chair of the ODA’s Sports Dentistry Consultants, said that while Revel is said to be designed for adults, it is clearly intended for new users as well. Furthermore, it is not the taste but the nicotine, that attracts users. "Addicted individuals are not concerned with taste, but rather with results. The flavored brands of smokeless or spit tobacco are used to initiate new users, making the taste palatable while addicting the individual with nicotine—and putting them at risk for cancer because of the carcinogens."

In addition to nicotine, smokeless tobacco products often contain ingredients such as cadmium (used in car batteries), formaldehyde(Drug information on formaldehyde) (for embalming), benzopyrene (cancer-causing agent), and other chemicals.

Pages: 1  2  
Next
 

Join the Conversation

Want to join the conversation? If you're a healthcare professional, we'd like to hear your comments. Just sign in or register today to become part of our growing, online community.






 
TOPIC INDEX

Cancer Types

 
  • Breast
  • Breast (HER2+)
  • Breast (Triple-Negative)
  • CML
  • Colorectal
  • Gastrointestinal
  • GIST
  • Genitourinary
  • Gynecologic
  • Head & Neck
  • Hematology
  • Kidney (Renal Cell)
  • Leukemia
  • Lung
  • Lymphoma
  • Melanoma
  • Multiple Myeloma
  • Ovarian
  • Prostate
  • Sarcoma

Supportive Care

More Topics

  • Bone Metastases
  • End-of-Life Care
  • Palliative Care
  • Ethics in Oncology
  • Practice Management
  • Practice & Policy


All Topics 


 
IMAGE IQ

Lower Back Pain in an Elderly Man With a History of Localized Prostate Cancer
James B. Yu, MD1 , May 17, 2013

A 70-year-old man with a history of localized prostate cancer treated with whole-pelvis radiation therapy with a boost to the prostate, in conjunction with androgen deprivation therapy 7 years prior, presented with lower back pain. A bone scan revealed an area of activity in the sacrum. What is the most likely diagnosis?

More Image IQs 

 
FROM PHYSICIANS PRACTICE
Primary Care Can't Thrive Without Nurse Practitioners
Courtney H. Lyder, ND,  May 17, 2013
With a projected shortfall of primary-care physicians, it's time for alternate solutions to patient care. Nurse practitioners are one logical remedy.
VWhat Physicians Can Learn from the Allscripts EHR Lawsuit
Marisa Torrieri,  May 16, 2013
Lawsuit prompts question: What should physicians do to ensure they end up with a great EHR instead of buyer’s remorse?
Eight Ways ICD-9 Will Still Matter to Medical Practices
Brenda Edwards, CPC,  May 15, 2013
What should your medical practice do with your ICD-9-CM book after October 1, 2014? Keep it.
Seven Ways Technology Can Speed Up Patient Collections
Cheyenne Brinson,  May 15, 2013
Failing to adopt widely available billing and collections technology can cost medical practices big. Here's how to do it right.
Four Reasons Private Medical Practice is Becoming Extinct
Carol Stryker,  May 15, 2013
It’s becoming increasingly difficult for private medical practices to thrive. Here’s what’s driving the trend toward consolidation.
 

 

 
MOST POPULAR
  • Most Popular
  • Most Emailed
  • Most Recent
  • Skin Lesions
  • Colorectal Lesions
  • “This Is My Last Day on Earth”
  • Dermatologic Adverse Events Associated With Targeted Therapies
  • Slide Show: Squamous Cell Carcinoma of the Head and Neck
  • “This Is My Last Day on Earth”
  • Dermatologic Adverse Events Associated With Targeted Therapies
  • Recurrent Epithelial Ovarian Cancer: An Update on Treatment
  • ONS: Understanding Spirituality and How It Can Be Used to Help Patients
  • Colorectal Lesions
  • New AUA Guidelines for Prostate Cancer Screening
  • 50 Shades of Pink—And Why It Helps to Know the Difference
  • Genomics Studies Identify Testicular Cancer Risk Variants
  • Lower Back Pain in an Elderly Man With a History of Localized Prostate Cancer
  • FDA Approves Erlotinib (Tarceva) as First-Line Lung Cancer Therapy for Certain Patients
Click here to subscribe to our newsletter
 
COMMENTS
  • Most Commented
  • Most Recent
  • “This Is My Last Day on Earth”
  • Financial Toxicity, Part II: How Can We Help With the Burden of Treatment-Related Costs?
  • Patient Quality of Life Endpoints in Oncology Trials, Part II
  • Who's Coding Whom?
  • “How Do I Say This Nicely? Your Oncologist Wasn't Following Guidelines”
  • Study: Cholesterol Drugs Reduced Risk of Prostate Cancer Death
  • “This Is My Last Day on Earth”
  • ONS: Safe Handling of Chemotherapy
  • Financial Toxicity, Part II: How Can We Help With the Burden of Treatment-Related Costs?
  • Conflicts of Interest in Medicine: What About Ties to Payers?
Click here to subscribe to our newsletter



CancerNetwork on Facebook

CancerNetwork | ConsultantLive | Diagnostic Imaging | Musculoskeletal Network | OBGYN.net | PediatricsConsultantLive |
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources

© 1996 - 2013 UBM Medica LLC, a UBM company
Privacy Statement - Terms of Service - Advertising Information - Editorial Policy Statement - UBM Medica Network Privacy Policy